# A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

> **NCT06159101** · PHASE1 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 304 (estimated)

## Conditions studied

- Healthy Male Volunteers

## Interventions

- **DRUG:** HLX13
- **DRUG:** CN-sourced ipilimumab
- **DRUG:** EU-sourced ipilimumab group
- **DRUG:** US-sourced ipilimumab group

## Key facts

- **NCT ID:** NCT06159101
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-28
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06159101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06159101, "A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06159101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*